1. Pink Sheet

Patent Thicketing Provision Cut From Bill Passed By US Senate Judiciary Committee

 
• By Brenda Sandburg

Legislation was also revised to enable manufacturers to justify withdrawing, discontinuing or switching product for follow-on; bills restricting citizen petitions, tribal sovereign immunity also clear committee.

Capitol Building, Washington DC
Affordable Prescriptions for Patients Act specifies FTC authorities to pursue product hopping. • Source: Shutterstock

The sponsors of legislation to curtail so-called product hopping and patent thicketing by product innovators cut the section on patent thickets in a manager's amendment that cleared the US Senate Judiciary Committee on 27 June.

The bill, Affordable Prescriptions for Patients Act, S. 1416, would amend the Federal Trade Commission Act to prohibit anticompetitive behaviors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.